Raporty

52/2014 Conclusion of a loan agreement under general conditions

The Management Board of Centrum Medyczne ENEL-MED S.A. (hereinafter: the “Company) hereby informs that, on 1 September 2014 the Company and ING Finance Sp. z o.o. (hereinafter: (“ING”) concluded a loan agreement under general conditions.

In accordance with the signed agreement ING assumes the obligation to grant the Company a loan for acquisition of objects of funding, selected by the Company, in particular medical equipment (resonances, ultrasound cameras) or any other type of objects approved by ING in witting.

The period of availability of funds allocated for financing commences as of the day the collaterals are determined (as referred to hereinbelow) and ends on 30 June 2015. If during the period of the funds availability the Company does not use fully the maximum loan value, in the second quarter of 2015 ING shall file to a relevant credit committee an application for extension of the period of the funds availability for the next period.

Collaterals:

– for each particular loan agreement in blanco promissory note issued each time by the Company for the benefit of ING with promissory note declaration in a form and of the content determined in each individual loan agreement;

– registered pledge agreement upon each object of funding concluded between ING as the pledgee and the Company as the pledger;

– agreement on assignment of rights under insurance policies for collateral, concluded between ING as the assignee and the Company as the assignor to each loan agreement.

The total initial value of the objects of funding shall not be less than PLN 50.000,00 including VAT and shall not exceed the amount of PLN 17.400.000,00.

ING shall each time offer the Company a loan term but not longer than 60 months. Payment of instalments shall be made based on 1-month WIBOR plus a margin. The currency utilised for future loan agreements shall be PLN. Other currency may be used if the parties agree on such currency in a written form.

This agreement has been considered as a significant one as its value exceeds 10% of the Issuer’s equity.